文献速递消化道肿瘤与早癌消化内镜

基线腺瘤与第三次结肠镜进展性病变风险:新罕布什尔结肠镜注册数据

Association Between Index Adenomas and Advanced Findings at Third Colonoscopy: Data From the New Hampshire Colonoscopy Registry.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-03-27

基于新罕布什尔结肠镜注册的前瞻性数据,纳入3171例首次监测结肠镜无息肉的患者,评估基线腺瘤与第二次监测结肠镜进展性病变的风险。结果显示基线为进展性腺瘤或5个以上非进展性腺瘤者,第二次监测发现进展性病变的风险升高,且独立于腺瘤检出率等质量指标和已知危险因素。

要点

  • 基线为进展性腺瘤或5个以上非进展性腺瘤者,第二次监测结肠镜进展性病变风险增加。
  • 基线1-2个非进展性腺瘤者第二次监测进展性病变风险亦轻度升高(aRR 1.67)。
  • 该关联独立于腺瘤检出率、吸烟和体重指数等已知危险因素。

核心结论

  • 基线为进展性腺瘤或5个以上腺瘤且首次监测结肠镜无息肉的患者,第二次监测结肠镜发现进展性病变的风险增加。
  • 该关联独立于腺瘤检出率及吸烟、体重指数等已知危险因素。

研究设计与样本

  • 前瞻性队列研究,使用新罕布什尔结肠镜注册数据,纳入3171例患者。
  • 患者接受两次监测结肠镜(间隔>12个月),首次监测无息肉,无既往结直肠肿瘤、遗传综合征或炎症性肠病。
  • 按基线结肠镜结果风险分层:无腺瘤;1-2个非进展性腺瘤;3-4个非进展性腺瘤;进展性腺瘤/5个以上非进展性腺瘤。
  • 参考组为基线和首次监测均无腺瘤者,采用泊松模型校正结直肠癌家族史、吸烟、腺瘤检出率和基线锯齿状息肉。

主要发现

  • 第二次监测结肠镜进展性病变发生率:无基线腺瘤者3.7%(95%CI 3.0%-4.6%),1-2个非进展性腺瘤者6.3%(95%CI 4.9%-8.2%),3-4个非进展性腺瘤者4.3%(95%CI 1.5%-12.0%),进展性腺瘤/5个以上非进展性腺瘤者6.2%(95%CI 4.0%-9.4%)。
  • 第二次监测进展性病变的校正率比:进展性腺瘤/5个以上非进展性腺瘤者2.12(95%CI 1.06-4.25),3-4个非进展性腺瘤者1.23(95%CI 0.26-5.74),1-2个非进展性腺瘤者1.67(95%CI 1.01-2.74)。
  • 第二次监测进展性腺瘤或结直肠癌的校正率比:进展性腺瘤/5个以上非进展性腺瘤者3.47(95%CI 1.46-8.24),3-4个非进展性腺瘤者2.26(95%CI 0.48-10.67),1-2个非进展性腺瘤者1.84(95%CI 0.94-3.59)。

关键数值与推荐

  • 进展性结局定义为>1 cm或异型增生的锯齿状息肉、进展性腺瘤或结直肠癌。
  • 第二次监测进展性病变风险在基线进展性腺瘤/5个以上非进展性腺瘤者中校正率比2.12(95%CI 1.06-4.25)。
  • 第二次监测进展性腺瘤或结直肠癌风险在基线进展性腺瘤/5个以上非进展性腺瘤者中校正率比3.47(95%CI 1.46-8.24)。

临床怎么用

  • 对于基线为进展性腺瘤或5个以上非进展性腺瘤且首次监测结肠镜无息肉的患者,应重视第二次监测结肠镜的进展性病变风险。
  • 风险分层可结合基线腺瘤数量和组织学,独立于腺瘤检出率等质量指标。

局限性

  • 证据来自观察性注册数据,可能存在未测量混杂因素。
  • 部分风险分层亚组样本量较小,置信区间较宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The United States Multi-Society Task Force for Colorectal Cancer (CRC) provides recommendations for the second surveillance colonoscopy for patients with adenomas on index exam. However, evidence which informs risk at second surveillance is limited due to lack of data on quality measures and known risk factors. We evaluated the risk for an advanced outcome on second surveillance colonoscopy for patients with index adenomas and a first surveillance colonoscopy without polyps, while accounting for risk factors and adenoma detection rates. METHODS: Our primary outcome was the detection of advanced outcomes at second surveillance colonoscopy as defined by large (>1 cm)/dysplastic serrated polyps, advanced adenoma (AA), or CRC. Another outcome was AA or CRC. We used prospectively collected New Hampshire Colonoscopy Registry (NHCR) data. Patients had 2 surveillance colonoscopies >12 months apart and a first surveillance colonoscopy without polyps. Patients had no previous colorectal neoplasia, genetic syndromes, or inflammatory bowel disease. Patients were risk-stratified based on index colonoscopy findings; no adenomas; 1 to 2 nonadvanced adenomas; 3 to 4 nonadvanced adenomas; AA /5+ nonadvanced adenomas. The reference group had no adenomas on index and first surveillance. Covariates in the Poisson model included family history of CRC, smoking, adenoma detection rates, and serrated polyps on index exam. RESULTS: We included 3171 patients from the NHCR, 3.7% (95% confidence interval [CI], 3.0%-4.6%) of patients with no index adenomas, 6.3% (95% CI, 4.9%-8.2%) with 1 to 2 index nonadvanced adenomas, 4.3% (95% CI, 1.5%-12.0%) with 3 to 4 index nonadvanced adenomas, and 6.2% (95% CI, 4.0%-9.4%) with 5+ nonadvanced adenomas and/or AAs developed advanced outcomes on second surveillance colonoscopy. The adjusted rate ratio for advanced outcomes on second surveillance exam was 2.12 (95% CI, 1.06-4.25) in patients with AA/5+ nonadvanced adenomas, 1.23 (95% CI, 0.26-5.74) in patients with 3 to 4 nonadvanced adenomas, and 1.67 (95% CI, 1.01-2.74) in patients with 1 to 2 nonadvanced adenomas. The adjusted rate ratio for AA or CRC on second surveillance exam was 3.47 (95% CI, 1.46-8.24) in patients with AA/5+ nonadvanced adenomas, 2.26 (95% CI, 0.48-10.67) in patients with 3 to 4 nonadvanced adenomas, and 1.84 (95% CI, 0.94-3.59) in patients with 1 to 2 nonadvanced adenomas. CONCLUSIONS: Our analysis demonstrated that patients with AAs or 5+ adenomas on index exam and a normal first surveillance exam have increased risk for advanced findings on second surveillance colonoscopy. This association is independent of quality measures including adenoma detection rate and known risk factors such as smoking and body mass index.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Javidi DJ, Dairi O, MacKenzie TA, et al. Association Between Index Adenomas and Advanced Findings at Third Colonoscopy: Data From the New Hampshire Colonoscopy Registry. Clin Gastroenterol Hepatol. 2026. PMID: 41905521. doi:10.1016/j.cgh.2026.03.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。